Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03NCF
|
|||
| Former ID |
DNC013043
|
|||
| Drug Name |
Tyr-Pro-Hfe-Pro-NH2
|
|||
| Synonyms |
CHEMBL380286; Tyr-Pro-Hfe-Pro-NH2
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C29H37N5O5
|
|||
| Canonical SMILES |
C1CC(N(C1)C(=O)C(CCC2=CC=CC=C2)NC(=O)C3CCCN3C(=O)C(CC4=CC=C(C=C4)O)N)C(=O)N
|
|||
| InChI |
1S/C29H37N5O5/c30-22(18-20-10-13-21(35)14-11-20)28(38)34-17-5-9-25(34)27(37)32-23(15-12-19-6-2-1-3-7-19)29(39)33-16-4-8-24(33)26(31)36/h1-3,6-7,10-11,13-14,22-25,35H,4-5,8-9,12,15-18,30H2,(H2,31,36)(H,32,37)/t22-,23-,24-,25-/m0/s1
|
|||
| InChIKey |
SJJQQBJUOIMODQ-QORCZRPOSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Opioid receptor mu (MOP) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Estrogen signaling pathway | ||||
| Morphine addiction | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Enkephalin release | ||||
| Pathway Interaction Database | IL4-mediated signaling events | |||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | TCR Signaling Pathway | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Peptide GPCRs | ||||
| Opioid Signalling | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.